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BACKGROUND: A fibroblast growth factor 2 (FGF2)-targeted adenoviral system can alter viral tropism and allow for improved
transduction and reduced systemic toxicity. This study is to investigate if the FGF2-targeted adenoviral mutant Nijmegen breakage
syndrome 1 (FGF2-Ad-NBS1) gene transfer can enhance cisplatin chemosensitisation not only by targeting DNA repair, but also
through the induction of antiangiogenesis, whereas at the same time reducing toxicities in treating head and neck squamous cell
carcinoma (HNSCC).
METHODS: The human HNSCC cell line was treated in vitro and in a nude mouse xenograft model. We conducted verification of
binding ability of mutant NBS1 and downregulation of MRN complex, evaluation of transduction efficiency and combined antitumour
activities. The antiangiogenesis mechanism was also investigated. Finally, we estimated the distribution of adenoviral vector in the liver.
RESULTS: The mutant NBS1 protein retains the binding ability and effectively suppresses the expression level of the MRN in infected
cells. Transduction efficiency in vitro and cisplatin chemosensitisation were upregulated. The FGF2-Ad-NBS1 also showed detargeting
the viral vectors away from the liver. The downregulation of NF-kB expression was supposed to correlate with increased
antiangiogenesis.
CONCLUSIONS: FGF2-targeted adenoviral system enhances the cisplatin chemosensitisation of mutant NBS1 and may avoid viral-
associated liver toxicities.
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Cisplatin is one of the most commonly used agents for the
treatment of the head and neck squamous cell carcinoma
(HNSCC). Cisplatin cytotoxicity results from the formation of
DNA monoadducts and crosslinks, which, in turn, promote
the development of apoptosis-inducing double-strand breaks
(DSBs) during replication (Chu, 1994; Perez, 1998). Unfortunately,
cisplatin-based tumour resistance is often acquired after repeated
cycles of therapy or owing to inherent resistance to cisplatin in
clinical practice. The development of resistance to cisplatin is
considered one of the major factors of treatment failure in HNSCC
(Kelland, 2007). A major factor in the development of chemo-
resistance is the enhanced DNA repair ability of tumour cells
preventing the accumulation of lethal DNA damage from cytotoxic
agents (Drummond et al, 1996; Fink et al, 1996; Perez, 1998;
Kartalou and Essigmann, 2001; Martin et al, 2008). Therefore,
interruption of cellular DNA repair mechanisms can sensitise
tumour cells to DNA-damaging agents (O’Malley et al, 2003; Tran
et al, 2004; Abuzeid et al, 2009).
One of the critical components in the DNA DSB repair system is
the protein complex made up of the MRE11, RAD50 and NBS1
proteins (MRN complex) (Williams et al, 2007). Mutations in the
NBS1 gene that codes for the NBS1 protein cause the congenital
disorder Nijmegen breakage syndrome (NBS). Nijmegen breakage
syndrome 1 participates in the recognition of DNA damage
and subsequent recruitment of MRE11 and RAD50, forming DNA
repair complexes at the sites of DSB damage (Kobayashi et al,
2004). Patients with NBS are characterised by stunted growth,
microcephaly, marked sensitivity to ionising radiation, chromo-
some translocations, and increased incidence of leukaemia and
lymphoma. The pathogenesis of NBS arises from premature
truncation of the protein product (Varon et al, 1998). This dis-
order underscores the fact that disruption of MRN function leads
to a dysfunction of DNA DSB repair system and consequently
sensitises tumour cells to DNA damage agents, including cisplatin.
We have developed an adenoviral vector containing mutant NBS1
(Ad-NBS1) or RAD50 (Ad-RAD50) for the purpose of disrupting
MRN function and sensitising cells for cisplatin. In human HNSCC
cell lines in vitro, Ad-NBS1 gene transfer significantly increased
cisplatin-induced DNA DSBs, cytotoxicity and inhibited tumour
cell growth (Tran et al, 2004). Also, it has shown a significant
antitumour effect after combination with radiation therapy
(O’Malley et al, 2003). A combination of cisplatin and mutant
RAD50 therapy also produced significant tumour cytotoxicity
in vitro, with a corresponding increase in DNA damage and
telomere shortening. In cisplatin-resistant human HNSCC xeno-
grafts in nude mice, this combination therapy caused dramatic
tumour regression with increased apoptosis (Abuzeid et al, 2009).
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sHead and neck squamous cell carcinomas are suitable for local
viral vector delivery, because most of them are locally accessible
and can be directly approached in our clinical practice. Adenoviral
transduction efficiency in most cells is highly dependent on the
expression of its primary receptor, coxsackie virus-adenovirus
receptor (CAR) (Li et al, 1999). Low and varied expression of
CAR could be a significant factor for low transduction efficiencies.
Several studies have investigated the benefit of adenoviral targeting
from its tropism for CAR to the fibroblast growth factor recep-
tors (FGFRs), which significantly increases adenoviral gene
transduction to FGFR-positive cells, and which are less prevalently
expressed on non-cancerous tissues (Goldman et al, 1997; Rogers
et al, 1997; Gu et al, 1999). Fibroblast growth factor 2 (FGF2)-
targeted adenoviral conjugates (FGF2-Ad) utilises FGF2 as the
targeting ligand. This FGF2-targeted adenoviral system has
achieved efficient gene transfer in previously reported ovarian,
pancreatic, skin and lung cancer models, as well as in HNSCC and
in endothelial cells (ECs) (Rogers et al, 1997; Rancourt et al, 1998;
Kleeff et al, 2002; Qin et al, 2005; Saito et al, 2009). Fibroblast
growth factor 2 exhibits its biological activities by high affinity
binding to FGFRs (particularly FGFR1 and FGFR2). The expression
levels of FGFR1 and FGFR2 are known to be upregulated in cancer
cells and ECs in HNSCC (Dellacono et al, 1997; Wakulich et al,
2002). Given the relationship between FGF2 expression and ECs,
and the low level of CAR expression on ECs in HNSCC, there may
be a potential role for FGF2-targeted therapy as an additional
therapeutic strategy of antiangiogenesis.
Nuclear factor-kB is a well-known transcription factor that is
responsible for regulating many genes involved, such as immune
response differentiation, proliferation, angiogenesis and apoptosis
(Sun and Zhang, 2007). It is regulated by the Ras/MEK signalling
pathway, which is parallel with PI3K/AKT angiogenesis pathway
(Jiang and Liu, 2008). Therefore, the expression level of NF-kB
may vary from the status of angiogenesis in tumour.
In this study, we first evaluated if disruption of MRN function
by Ad-NBS1 sensitised HNSCC to cisplatin in vivo. Next, we
examined if Ad-NBS1 specifically targeting FGFRs could enhance
the therapeutic benefit with cisplatin treatment through not only
targeting cancer cells, but also disrupting angiogenesis. The status
and mechanism of antiangiogenesis after FGF2-targeted Ad-NBS1
delivery and the possibility of systemic toxicity reduction by
altering organ distribution were also investigated.
MATERIALS AND METHODS
Cell line
The human HNSCC cell line JHU006 (originally derived at the
Johns Hopkins University Head and Neck Laboratories, Baltimore,
MD, USA) was used in all experiments. This cell line has derived
from human tumour explants, has been well characterised and is
known to express wild-type MRE11, RAD50, NBS1, high FGFRs
and low CAR. The 50% inhibitory concentration (IC50) of 72h after
cisplatin administration for this cell line is 2.6mgml
 1. Cells were
propagated as described previously (Li et al, 2002).
Animals
Animal experiments were performed on 6-week-old BALB/c nude
mice maintained in an animal facility. Animals were cared for and
used in accordance with protocols approved by the Animal Care
and Use Committee of The University of Pennsylvania.
Recombinant adenoviral vector and FGF2-Fab0 adenovirus
conjugate
An adenovirus construct containing the mutant NBS1 cDNA for
the C-terminal 300 amino acids of NBS1 and green fluorescent
protein (GFP) under the control of two independent cytomegalo-
virus (CMV) promoters (Ad-NBS1) was created (Li et al, 1999).
Green fluorescent protein-expressing adenovirus under the control
of CMV promoters (Ad-GFP) was used for control virus. A
bi-functional FGF2-Fab0conjugate molecule was prepared based on
published protocols (Doukas et al, 1999) and obtained from
Selective Genetics Inc. (San Diego, CA, USA).
Western blot analysis
The expression of wild-type MRE11, RAD50, NBS1 and mutant
NBS1 proteins was detected using western blot analysis as
described previously (Tran et al, 2004; Abuzeid et al, 2009).
Recombinant adenovirus (Ad-NBS1 or Ad-GFP) was introduced
into JHU006 cell cultures at a multiplicity of infection (MOI) of 10
for 4h at 371C. Polyclonal rabbit anti-human MRE11, RAD50,
NBS1, which recognises both wild-type and mutant NBS1, and
b-actin (Novus Biologicals, Littleton, CO, USA) was used as the
primary antibody at a concentration of 1:1000. MagicMark XP
western protein standard (Invitrogen Corporation, Carlsbad, CA,
USA) was used to monitor electrophoresis progression. Western
Breeze chemiluminescent immunodetection system (Invitrogen)
was used to observe protein bands. Experiments were repeated in
triplicate. Images of the protein bands were acquired using a
Canon Digital Rebel XTI camera (Canon USA Inc., New York, NY,
USA). Densitometric analysis of the films was performed using the
ImageJ 1.43 software, which is publically available through the
National Institute of Health.
The expression of NF-kB protein after FGF2-targeted NBS1 gene
delivery in vitro was also detected using western blot analysis,
same as described above. Cultured JHU006 cells were split into
five groups: mock-treated PBS as ‘Control’, Ad-GFP (Control
virus), Ad-NBS1, FGF2-Fab0-conjugated Ad-GFP (FGF2-Ad-GFP)
and FGF2-Ad-NBS1. Recombinant adenovirus- or FGF2-Fab0-
conjugated adenovirus was introduced at an MOI of 5 for 4h at
371C and then cultured for 72h. Polyclonal rabbit anti-human
NF-kB (Cell Signaling Technology, Danvers, MA, USA) and
polyclonal rabbit anti-b-actin (Novus Biologicals, Littleton, CO,
USA) were used at a concentration of 1:1000 as primary
antibodies. Densitometric analysis of the films was performed
using the ImageJ 1.43 software, which is publically available
through the National Institute of Health. Experiments were
repeated in triplicate.
Co-immunoprecipitation
Co-immunoprecipitation (Co-IP) was conducted to verify the
structural integrity between MRE11 and NBS1 following Ad-NBS1
infection in tumour cells as described previously (Abuzeid et al,
2009). JHU006 cells were either untreated or infected with
Ad-NBS1 or Ad-GFP at an MOI of 10 for 24h. Monoclonal mouse
anti-human MRE11 antibody (Novus Biologicals, Littleton, CO,
USA) was used to pull down the components of the MRN complex
at a concentration of 1:1000. The immunoprecipitates were
analysed by western blot analysis.
Transduction efficiency and tumour cell growth in vitro
To investigate the transduction efficiency and cisplatin chemo-
sensitisation effect after FGF2-targeted adenoviral gene delivery,
3 10
3 JHU006 cells were plated in 96-well tissue culture plates.
Wells were split into eight groups: mock-treated PBS as ‘Control’,
cisplatin, Ad-NBS1, Ad-NBS1/cisplatin, FGF2-Fab0-conjugated
Ad-NBS1 (FGF2-Ad-NBS1) and FGF2-Ad-NBS1/cisplatin. Cells were
incubated with any of the adenovirus or PBS at an MOI of 5 or 10.
After 24h, cisplatin was added at a concentration of 0.3mgml
 1.
The transduction efficiencies of Ad-NBS1 and FGF2-Ad-NBS1
in vitro were evaluated by GFP expression at 1 and 3 days after
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streatment. Views of each well were digitally recorded at 100-fold
magnification under fluorescent microscopy (Eclipse TS100,
Nikon, Tokyo, Japan). The average intensity of GFP expression
was obtained with the assistance of IP Lab software (Scanalytics
Inc., Fairfax, VA, USA).
The tumour cell growth was evaluated by MTT assay for
6 consecutive days (day 0–5) as described previously (Araki et al,
2008). The optical density was determined by spectrophotometry
(MRX II, Dynex Technologies, Chantilly, VA, USA).
Xenograft tumours in vivo
Tumours were established in the right flank of nude mice by a
subcutaneous (s.c.) injection of 1.0 10
7 JHU006 cells. At 14 days
after tumour injection, tumours were surgically exposed and
measured in three dimensions. Subsequently, intratumoral injec-
tions of 50ml of adenoviral vectors (3.0 10
8PFUml
 1) or PBS
were carried out using a Hamilton syringe. Cisplatin was
intraperitoneally injected in cisplatin-treated groups at 5mgkg
 1
as a regular dose or 3mgkg
 1 as a reduced dose. Tumour masses
were measured again in three dimensions and harvested at the
time of termination.
For the first trial, to investigate the cisplatin chemosensitisation
effects after Ad-NBS1 transfer, 30 mice were randomly divided into
six groups: PBS as ‘Control’, Reduced dose of cisplatin (Reduced
cisplatin), Regular dose of cisplatin (Regular cisplatin), Ad-NBS1,
Ad-NBS1/Reduced cisplatin and Ad-NBS1/Regular cisplatin. The
second trial was performed to investigate the advantage in cis-
platin chemosensitisation after FGF2-targeted Ad-NBS1 therapy.
A total of 25 mice were randomly divided into five groups: PBS,
Regular cisplatin, Ad-NBS1/Reduced cisplatin, Ad-NBS1/Regular
cisplatin and FGF2-Ad-NBS1/Reduced cisplatin. The tumour
volume was measured 17 days after treatments, apoptosis
induction was evaluated in both first and second trials and
angiogenesis was evaluated in the second trials.
To confirm the potential reduction of systemic side effects and
to detect the mechanism of the antiangiogenesis effect, the third
trial was performed. In total, 60 mice were randomly divided into
three groups: PBS, Ad-NBS1 and FGF2-Ad-NBS1. Five mice of
each group were euthanised at 1, 3, 7 and 14 days after viral injec-
tion, and tumours and livers were harvested. The existence of
adenovirus in the liver was investigated by polymerase chain
reaction (PCR).
Apoptosis detection
The ApopTag Peroxidase In-Situ Apoptosis Detection Kit
(Millipore, Billerica, MA, USA) was used to detect apoptosis. The
staining was performed following the manufacturer’s protocol and
slides were viewed under the microscope (Eclipse 80i, Nikon,
Tokyo, Japan). Four randomly selected views at 200-fold magni-
fication were digitally recorded in each tumour. All positive cells
within the view were counted.
Immunohistochemistry
Immunohistochemistry was performed using rat monoclonal anti-
CD31 (PECAM-1) antibody (BD PharMingen, San Diego, CA, USA)
and the VECTASTAIN Elite ABC kit (Vector Laboratories Inc.,
Burlingame, CA, USA) to visualise ECs (CD31) of the second trial.
To assess microvessel growth, four views ( 200) were digitally
recorded for each tumour to cover the greatest anti-CD31 staining
area for the estimation of microvessel development (Weidner,
1995). The relative percentage of CD31 staining positive area (%
region of interest: %ROI), which represents the microvessel
density (MVD), within each view was measured with the assistance
of IP Lab software.
Virus detection in the liver
Total DNA was isolated from the tissues of harvested livers using
DNeasy, Blood & Tissue Kit (Qiagen Science, Germantown, MD,
USA) in accordance with the instructions. Polymerase chain
reaction was performed in PCR buffer. Specific oligonucleotide
primers were designed to amplify Ad-NBS1 gene-specific derived
DNA (forward, 50-TTGACGCAAATGGGCGGTAGG-30; reverse,
50-CTGCAGCATGAGATTTACTGG-30), which produces a 381-bp
amplified product. The PCR amplification program comprises 35
cycles of: denaturation at 941C for 45s, annealing at 601C for 45s
and extension at 721C for 45s.
Statistical analysis
Mann–Whitney analysis was applied using STATMOST (Detaxion
Software Inc., Los Angels, CA, USA) to determine the statistical
significance.
RESULTS
Transgene expression of mutant NBS1 disrupts the MRN
functional unit
Co-immunoprecipitation was used to confirm that MRE11 forms
complex with wild-type NBS1 or mutant NBS1. In non-infected
cells or Ad-GFP-infected cells, anti-MRE11 antibody co-precipi-
tated NBS1 (95kDa; Figure 1A). After Ad-NBS1 infection, anti-
MRE11 antibody was able to co-precipitate both NBS1 and mutant
NBS1 (37kDa; Figure 1A). These findings indicate that both wild-
type and mutant NBS1 protein retain binding ability to the MRE11/
RAD50 complex. Western blot after Co-IP showed that there was a
significant downregulation of wild-type NBS1 protein in cells
infected with Ad-NBS1 relative to non-infected cells (Figure 1A).
These results showed that Ad-NBS1 effectively suppresses the
expression of the MRN functional unit in infected cells.
MRN protein expression in Ad-NBS1-infected
or -uninfected JHU006 cells
We confirmed the expression of wild-type MRE11 (81kDa;
Figure 1B), RAD50 (153kDa; Figure 1C) and NBS1 (Figure 1D)
proteins in JHU006 cells by western blot. The wild-type MRE11
proteins expression showed no significant differences between
uninfected and Ad-NBS1-infected JHU006 (Figure 1B). The
expressions of wild-type RAD50 (Figure 1C; Po0.05) and NBS1
(Figure 1D; Po0.01) were significantly reduced in Ad-NBS1-
infected JHU006 cells when compared with Ad-NBS1-uninfected
cells. Adenoviral-green fluorescent protein did not show signi-
ficant difference when compared with control. It means that GFP
or CMV promoter does not affect the expression of MRN complex
in this cancer cells. Mutant NBS1 protein expression was observed
only in Ad-NBS1-infected JHU006 cells.
FGF2-targeted adenoviral system enhances transduction
efficiency in vitro
We investigated the benefit of FGF2-targeted adenoviral system in
gene transduction. The average relative intensity of GFP expres-
sion after FGF2-targeted Ad-NBS1 and non-targeted Ad-NBS1
gene transfer in the JHU006 cell line at MOIs 5 and 10 was
estimated at days 1 and 3 (Figure 2A and B). A significantly higher
intensity was observed at both days 1 and 3 in FGF2-Ad-NBS1
than in Ad-NBS1 (2.89±0.34 vs 1.00±0.14, Po0.01, 9.90±2.28
vs 5.73±0.95, Po0.01, respectively) at an MOI of 5 (Figure 2C).
In contrast, no significant difference was observed at an MOI of 10
at both days 1 and 3 (1.04±0.28 vs 1.00±0.17, Po0.01, 0.78±0.24
vs 0.86±0.08, Po0.01, respectively) (Figure 2D). These results
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sshowed that the FGF2-targeting system could achieve sufficient gene
transduction after a relative lower titre adenoviral administration.
FGF2-targeted Ad-NBS1 gene transfer enhances cisplatin
chemosensitisation in vitro
The benefit of FGF2-targeted adenoviral system in tumour
suppression was investigated using the MTT assay. JHU006 cells
were subjected to six interventions. The cell growth in Ad-NBS1/
cisplatin and FGF2-Ad-NBS1/cisplatin had a greater inhibition
than that in other groups at an MOI of 5 (Figure 3A). The cell
growth of Ad-NBS1/cisplatin and FGF2-Ad-NBS1/cisplatin also
had a greater inhibition than that of the Control or Cisplatin
groups at an MOI of 10 (Figure 3B); however, no difference was
observed when compared with that of Ad-NBS1 or FGF2-Ad-NBS1.
These results at an MOI of 5 show that the tumour inhibition in
FGF2-Ad-NBS1/cisplatin has more effect at an early phase than
that of Ad-NBS1/cisplatin. This is consistent with the results of
the GFP expression in higher and earlier transduction of FGF2-
Ad-NBS1/cisplatin than that of Ad-NBS1/cisplatin. However, the
results at an MOI of 10 suggest that the transduction efficiency and
tumour growth inhibition reaches the maximum level in Ad-NBS1/
cisplatin at an MOI of 10. As a result, the FGF2-targeted system has
the potential of a lower titre administration of virus while still
achieving optimal cisplatin chemosensitisation effects.
Transgene expression of mutant NBS1 induces cisplatin
chemosensitisation in a mouse model with human HNSCC
A mouse model with JHU006 was used to evaluate whether the
in vitro cytotoxicity caused by the disruption of MRN function
translates into a beneficial effect in vivo. Mice were subjected to six
interventions (Figure 3C).
Ad-NBS1/Regular cisplatin had the greatest efficacy in reducing
tumour size. Adenoviral-NBS1/Reduced cisplatin also had better
tumour suppression. No significance was observed in tumour
shrinkage of Ad-NBS1/Reduced cisplatin when compared with
Ad-NBS1/Regular cisplatin or PBS/Regular cisplatin. These results
suggest that Ad-NBS1 induces a cisplatin chemosensitisation effect
and has the potential to reduce the dose of cisplatin administration
while achieving similar tumour suppressive effects of regular
cisplatin without Ad-NBS1 in vivo.
FGF2-targeted Ad-NBS1 gene transfer significantly
enhances cisplatin chemosensitisation in a mouse model
with human HNSCC
The same mouse model was used to further evaluate whether the in
vitro transduction efficiency and cytotoxicity after FGF2-targeted
Ad-NBS1 gene transfer translated into a beneficial effect on in vivo
tumour growth. Mice were randomly divided into five groups
(Figure 3D). Adenoviral-NBS1/Regular cisplatin and FGF2-Ad-
NBS1/Reduced cisplatin had the greatest efficacy in shrinking
tumour size and the effects were similar in both treatments. These
results show that cisplatin chemosensitivity following Ad-NBS1
gene transfer is significantly enhanced by the FGF2-targeting
system and allows for a reduction of cisplatin dose.
FGF2-targeted system does not show additional benefits on
Ad-NBS1-induced apoptosis in vivo
The number of apoptotic cells of the first animal trial was counted
to evaluate the in vivo cisplatin chemosensitisation effect after Ad-
NBS1 gene transfer (Figure 4A). The apoptotic index in the
Ad-NBS1/Regular cisplatin was highest of all groups. Adenviral-
NBS1/Reduced cisplatin exhibited a similar level in apoptosis
induction to the regular cisplatin without Ad-NBS1.
The number of apoptotic cells of the second trial following
FGF2-targeted Ad-NBS1 gene transfer was also evaluated
(Figure 4B). Adenoviral-uninfected PBS control with regular
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Figure 1 Transgene expression of mutant NBS1 interacts with MRN after Ad-NBS1 gene transfer and significantly reduces the expression of wild-type
RAD50 and NBS1. (A) Anti-MRE11 antibody Co-IP wild-type NBS1 in all cells. It indicated direct interaction between MRE11 and wild-type NBS1 (lanes 2,
4, 6 and 8). Mutant NBS1 was Co-IP in Ad-NBS1-infected cells, indicated direct interaction between MRE11 and mutant NBS1 (lane 8). A significant
downregulation of wild-type NBS1 protein was observed in cells infected with Ad-NBS1 (lane 8) relative to non-infected cells (lanes 2, 4 and 6). All lanes
shown were run simultaneously on a single gel as contiguous lanes. Lane 1: control cells; lane 2: control cells after Co-IP with MRE11 antibody; lane 3: cells
treated with cisplatin (0.3mgml
 1); lane 4: cisplatin-treated cells after Co-IP with MRE11antibody; lane 5: Ad-GFP-infected cells; lane 6: Ad-GFP-infected cells
after Co-IP; lane 7: Ad-NBS1-infected cells and lane 8: Ad-NBS1-infected cells after Co-IP with MRE11 antibody. (B–D) Wild-type MRE11 was not
downregulated after infection of JHU006 cells with Ad-NBS1 relative to non-infected controls or Ad-GFP controls (B). Downregulation of wild-type RAD50
(Po0.05; C) and NBS1 proteins (Po0.01; D) is seen after infection with Ad-NBS1 when compared with non-infected controls or Ad-GFP controls.
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Figure 3 Fibroblast growth factor 2-targeted Ad-NBS1 gene transfer sensitizes head and neck cancer with cisplatin-based chemotherapy in vitro and
in vivo. Tumour cell growth curve analysis in vitro at an MOI of 5 (A) and 10 (B) in six different treatment groups. Fibroblast growth factor 2-targeted
Ad-NBS1 with cisplatin group had the greatest tumour suppression effect at an MOI of 5 (A), whereas no difference was observed between FGF2-Ad-
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before and after treatments are shown in the mouse model. (C) The greatest tumour shrinkage occurred when Ad-NBS1 gene therapy was combined with
Regular cisplatin. The tumour treated with Ad-NBS1/Reduced cisplatin also showed better a tumour suppression effect when compared with the regular
dose of cisplatin-treated tumours. (D) The combination Ad-NBS1/Regular cisplatin and FGF2-Ad-NBS1/Reduced cisplatin had the greatest efficacy in
reducing tumour size and the effect was almost the same in both treatments. Fibroblast growth factor 2-Ad-NBS1 therapy enhances sensitivity for cisplatin
intensely and allows for reduction of cisplatin dose.
#Po0.01 when compared with Ad-NBS1/Regular dose of cisplatin,
##Po0.05 when compared with
Ad-NBS1/Regular dose of cisplatin,
þPo0.01 when compared with Ad-NBS1/Reduced dose of cisplatin,
þþPo0.05 when compared with Ad-NBS1/
Reduced dose of cisplatin, *Po0.01 when compared with FGF2-Ad-NBS1/Reduced dose of cisplatin, **Po0.05 when compared with FGF2-Ad-NBS1/
Reduced dose of cisplatin.
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scisplatin did not yield significant differences when compared with
any other adenoviral-infected groups. This result indicates that
apoptosis induction is not the sole factor of the enhanced cytotoxic
effect after FGF2-targeted delivery.
Antiangiogenesis is associated and enhanced
with FGF2-targeted Ad-NBS1 gene transfer
The level of CD31 positivity as measured in %ROI was used to
assess the level of angiogenesis in the second trial. A significantly
smaller %ROI was observed in the FGF2-Ad-NBS1/Reduced
cisplatin (2.40±1.78%) than all other groups (Figure 4C,D). These
results indicate that a potent antiangiogenesis effect was induced
after FGF2-targeted Ad-NBS1 gene transfer and this effect is
postulated to be associated with enhanced cisplatin chemosensi-
tisation.
NF-jB suppression regulates antiangiogenesis following
FGF2-targeted Ad-NBS1 gene transfer
To investigate the status and mechanism of an antiangiogenesis
effect after FGF2-targeted Ad-NBS1 gene transfer in vitro, the
expression levels of NF-kB proteins were analysed. NF-kBi sa
major factor in the Ras/Raf-1 angiogenesis pathway. The expres-
sion of NF-kB protein was significantly lower in FGF2-targeted
Ad-NBS1-infected cells (0.37±0.03) when compared with unin-
fected control (0.53±0.04, Po0.01), Ad-GFP-infected (0.55±0.05,
Po0.01), Ad-NBS1-infected (0.54±0.05, Po0.01) or FGF2-Ad-
GFP-infected (0.53±0.02, Po0.01) cells (Figure 5). These results
indicate that FGF2-targeted Ad-NBS1 may downregulate NF-kB
activity and downregulation of NF-kB may result in antiangio-
genesis in cancer cells.
FGF2-targeted gene delivery system alters adenovirus
distribution and detargets viral vectors from the liver
Viral toxicity in the liver has been a major concern following
adenoviral gene transfer. To investigate if the FGF2-targeted
system can alter the distribution of virus in the liver, the existence
of adenoviral vector in the liver after Ad-NBS1 treatment was
investigated by PCR. The adenoviral vector was detected as
positive bands only in the livers of the Ad-NBS1 group (Table 1).
No positive bands were found in the livers of control and FGF2-
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controls, Ad-GFP or Ad-NBS1. This result indicates that FGF2-targeted
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sAd-NBS1 (Table 1). Fibroblast growth factor 2-targeted system can
alter the tropism of the virus, prevent the localisation of adeno-
virus in the liver and may have the potential to reduce systemic
side effects.
DISCUSSION
This study showed that mutant NBS1 transfer significantly
increased chemosensitivity to cisplatin in vivo. These effects are
most likely due to molecular disruption of the MRN complex
through the expression of mutant NBS1. The mutant NBS1 used in
this study preserves the MRE11 interaction domain, but loses a
central region that includes several phosphorylation sites by ATM
and ATR kinases, and the forkhead-associated and BRCA1
C-terminus domains. These lost regions have the functions of
ATM activation, H2AX phosphorylation, MRN complex recruit-
ment to damaged sites of DSBs, cell cycle arrest and DSB repair
initiation (Rogers et al, 1997; Kobayashi et al, 2004; Czornak et al,
2008). Hence, a successful induction and expression of mutant
NBS1 results in losing many functions related to DNA DSB repair.
In this study, we showed that using Co-IP and western blot the
mutant NBS1 retains the binding ability to MRE11 and competi-
tively inhibits the binding of wild-type NBS1 to MRE11. Also, we
showed the downregulation of wild-type NBS1 and RAD50 after
Ad-NBS1 induction. These results are supposed to have occurred
by the loss of NBS1 functions, such as H2AX phosphorylation
or MRN complex recruitment to damaged sites of DSBs, and
consequently induces a dominant-negative downregulation of
MRN complex, possibly through inhibition of ATM activation
and H2AX phosphorylation (Kobayashi et al, 2004; Czornak et al,
2008). These results support our hypothesis that mutant NBS1
disrupts MRN function. Indeed, our previous report indicated
significantly increased cisplatin-induced DNA DSBs in vitro after
mutant NBS1 transduction (Tran et al, 2004).
This study proved the benefit of the FGF2-targeting system,
which has high transduction efficiency and enables a lower titre
viral administration while still maintaining in vitro and in vivo
tumour suppressive effect of cisplatin equivalent to a higher titre
non-targeting transfer. Although adenovirus-mediated gene trans-
fer is appealing, the infection of normal tissues and systemic
toxicities, mainly caused by viral entrance into the bloodstream
and viral trapping in the liver, limits the move into human
clinical trials. To overcome these issues, the FGF2-targeted
adenoviral system will be the most efficacious when applied to
cells that have low CAR and high FGFRs expression. In our
previous study, FGFR1 and FGFR2 expression was widely observed
in both tumour cells and ECs of the human HNSCC xenograft
model (Saito et al, 2009). Several studies have described a two- to
34-fold increase in intratumoral transduction efficiency (Rancourt
et al, 1998; Doukas et al, 1999; Qin et al, 2005) and a two-fold
increased transduction efficiency of adenoviral TK gene was
observed for human HNSCC (Saito et al, 2009). Our results also
support the benefit of FGF2 target with regard to intratumoral
transduction efficiency.
In addition, our results showed that the number of apoptotic
cells was not increased and microvessel density was decreased after
FGF2-Ad-NBS1/cisplatin treatment, suggesting successful trans-
duction into not only tumour cells, but also ECs by the FGF2-
targeted adenovirus system. The FGF2-targeted system has been
shown to induce highly efficient transduction in ECs that express
relatively low levels of CAR receptor (Gupta et al, 2006; Saito et al,
2009). It has been reported that angiogenesis is enhanced and the
expression levels of FGFR1 and FGFR2 are upregulated in cancer
cells and ECs in HNSCC (Dellacono et al, 1997; Riedel et al, 2000).
Although a direct effect in ECs as a result of mutant NBS1 gene
transfer is supposed to be one mechanism for antiangiogenesis
effect, downregulation of NF-kB expression after FGF2-targeted
Ad-NBS1 transduction that is seen in our study suggests other
suppression mechanisms.
NF-kB is a well-known transcription factor that is responsible
for regulating many genes, including angiogenesis and apoptosis
(Sun and Zhang, 2007). The NF-kB transcription factor family is
composed of p50, p52, RelA/p65, c-rel and Rel B. The homodimers
and heterodimers are sequestered in the cytoplasm as an inactive
form by the inhibitor of kappa B (IkB). Upon stimulation, the IkB
kinase complex phosphorylates the kB inhibitor, which then
releases NF-kB and allows its phosphorylation, nuclear transloca-
tion, binding and subsequent activation of target genes involved
in the regulation of cell proliferation, survival, angiogenesis
and metastasis (Brown et al, 1995). The inhibitor of NF-kB had
significant antitumour effects on oesophagus SCC by promoting
apoptosis, and inhibiting proliferation and angiogenesis, as well
as reduced the metastasis (Li et al, 2009). Furthermore, down-
regulation of NF-kB might consolidate DNA damage and apoptosis
induction because NF-kB orchestrates a cell survival pathway
together with the activation of cell cycle checkpoints and DNA
repair (Janssens and Tschopp, 2006). However, it is not clear as to
how NBS1 relates to the NF-kB. Some reports indicate that
when DSBs are generated by radiation, NBS-deficient cells exhibit
a delayed and strongly reduced level of NF-kB induction
(Habraken and Piette, 2006) and one cascade for NF-kB activation
depends on ATM, which closely interacts with NBS1 (Habraken
and Piette, 2006).
In this report, we have not shown the effect of FGF2-targeted
Ad-NBS1 gene transduction to the PI3K/AKT/HIF angiogenesis
pathway. However, many reports suggest that there is an inter-
action of NBS1 with key proteins involved in tumour angiogenesis
induction pathway such as PI3K and HDM2 (Alt et al, 2005; Chen
et al, 2008). We suppose that PI3K might be activated by NBS1, but
might be inactivated by mutant NBS1. It has been reported that the
reduced PI3K activity in NBS
 /  lymphoblasts is caused by an
impaired expression of the SRC family kinases (Sagan et al, 2008).
Similarly to our mutant NBS1, the NBS lymphoblastoid cell line
used in this report expressed NBS1 with the common 657del5
mutation, which preserves PI3K activation domain. Therefore, our
mutant NBS1 might have the potential to reduce PI3K activity and
may result in the inactivation of the PI3K/AKT angiogenesis
pathway. In fact, we have data with regard to the downregulation
of HIF-1a in vivo, which is the major factor in PI3K/AKT pathway
and regulates VEGF activation, after FGF2-targeted Ad-NBS1 gene
transduction (data not shown). Downregulation of both Ras/MEK
pathway and PI3K/AKT pathway may have synergistic effects in
inducing tumour angiogenesis (Jiang and Liu, 2008), and with
NF-kB downregulation, a potent inhibition of tumour angiogenesis
can be expected after FGF2-targeted Ad-NBS1 transduction.
Viral trapping in the liver is a major concern and an indicator
for systemic toxicity in the systemic administration of adenoviral
vector. It is reported that a majority of the adenoviral vector
accumulates in the liver, which can cause severe liver toxicity, and
that the liver is the most important organ to eliminate adenoviral
vector genome through the innate immune system (Akiyama et al,
2004; Yao et al, 2010). Although the liver is the major site of
Table 1 Distribution of Ad-NBS1 in the liver
PBS Ad-NBS1 FGF2-Ad-NBS1
Day 1 0/5 5/5 0/5
Day 3 0/5 4/5 0/5
Day 7 0/5 2/5 0/5
Day 14 0/5 2/5 0/5
Abbreviations: FGF2-Ad-NBS1¼fibroblast growth factor 2-targeted adenoviral
mutant Nijmegen breakage syndrome 1; PBS¼phosphate-buffered saline.
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sadenoviral localisation owing to its high CAR expression, the
FGF2-targeted adenoviral system can alter the distribution of the
virus and deterge the viral vector from the liver. The amount
of FGF2-targeted adenovirus delivery to the liver was shown as a
10- to 20-fold decrease, whereas an increase of transgene
expression in the tumour tissue was observed after systemic
administration (Printz et al, 2000). This decrease in liver
deposition translates into a significant reduction in subsequent
toxicity. In this study, a large systemic distribution of adenovirus
was not expected because the virus was administered via intra-
tumoral injection (Sewell et al, 1997). Nevertheless, the results
confirmed adenovirus existence with high rates in the liver after
Ad-NBS1 administration and absence of FGF2-targeted adeno-
virus. These results indicate that the FGF2-targeted adenoviral
system results in a more efficient system with reduced viral titre
application by its high transduction efficiency into cancer cells and
with concomitant lower levels of liver toxicity.
This study proves the efficacy of Ad-NBS1 gene transduction
in vivo to sensitise cisplatin chemotherapy by disrupting MRN
function in DNA DSBs repair systems. Furthermore, our find-
ings suggest that a more significant antitumour effect can be
achieved through not only enhanced tumour cytotoxicity, but
also antiangiogenetic effects when Ad-NBS1 is targeted to FGFRs.
Concurrently, FGF2-targeted system can reduce liver toxicity
by preventing adenoviral distribution. The great benefit of this
strategy supports further clinical trials in the treatment of
human HNSCC.
ACKNOWLEDGEMENTS
This work received grant from the Flight Attendant Medical
Research Institute and from the National Institute of Dental and
Craniofacial Research (5R01 DE14562).
REFERENCES
Abuzeid WM, Jiang X, Shi G, Wang H, Paulson D, Araki K, Jungreis D,
Carney J, O’Malley Jr BW, Li D (2009) Molecular disruption of RAD50
sensitizes human tumor cells to cisplatin-based chemotherapy. J Clin
Invest 119: 1974–1985
Akiyama M, Thorne S, Kirn D, Roelvink PW, Einfeld DA, King CR,
Wickham TJ (2004) Ablating CAR and integrin binding in adenovirus
vectors reduces nontarget organ transduction and permits sustained
bloodstream persistence following intraperitoneal administration. Mol
Ther 9: 218–230
Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM (2005)
Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand
break repair. J Biol Chem 280: 18771–18781
Araki K, Ahmad SM, Li G, Bray Jr DA, Saito K, Wang D, Wirtz U,
Sreedharan S, O’Malley Jr BW, Li D (2008) Retinoblastoma RB94
enhances radiation treatment of head and neck squamous cell
carcinoma. Clin Cancer Res 14: 3514–3519
Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U (1995) Control
of IkB-a proteolysis by site-specific, signal-induced phosphorylation.
Science 267: 1485–1488
Chen YC, Chiang HY, Yang HM, Chen PM, Chang SY, Teng SC,
Vanhaesebroeck B, Wu KJ (2008) Activation of phosphoinositide
3-kinase by the NBS1 DNA repair protein through a novel activation
motif. J Mol Med 86: 401–412
Chu G (1994) Cellular responses to cisplatin. The roles of DNA-binding
proteins and DNA repair. J Biol Chem 269: 787–790
Czornak K, Chughtai S, Chrzanowska KH (2008) Mystery of DNA repair:
the role of the MRN complex and ATM kinase in DNA damage repair.
J Appl Genet 49: 383–396
Dellacono FR, Spiro J, Eisma R, Kreutzer D (1997) Expression of basic
fibroblast growth factor and its receptors by head and neck squamous
carcinoma tumor and vascular endothelial cells. Am J Surg 174: 540–544
Doukas J, Hoganson DK, Ong M, Ying W, Lacey DL, Baird A, Pierce GF,
Sosnowski BA (1999) Retargeted delivery of adenoviral vectors through
fibroblast growth factor receptors involves unique cellular pathways.
FASEB J 13: 1459–1466
Drummond JT, Anthoney A, Brown R, Modrich P (1996) Cisplatin and
adriamycin resistance are associated with MutLalpha and mis-
match repair deficiency in an ovarian tumor cell line. J Biol Chem 271:
19645–19648
Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme ´ A, Christen RD, Howell
SB (1996) The role of DNA mismatch repair in platinum drug resistance.
Cancer Res 56: 4881–4886
Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP,
Baird A, Campain JA, Curiel DT (1997) Targeted gene delivery to
Kaposi’s sarcoma cells via the fibroblast growth factor receptor. Cancer
Res 57: 1447–1451
Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D’Andrea M,
Hoganson DK, Curiel DT, Douglas JT, Sosnowski BA, Baird A, Aukerman
SL, Pierce GF (1999) Fibroblast growth factor 2 retargeted adenovirus has
redirected cellular tropism: evidence for reduced toxicity and enhanced
antitumor activity in mice. Cancer Res 59: 2608–2614
Gupta V, Wang W, Sosnowski S, Hofman FM, Chen TC (2006) Fibroblast
growth factor-2-retargeted adenoviral vector for selective transduction
of primary glioblastoma multiforme endothelial cells. Neurosurg Focus
20: E26
Habraken Y, Piette J (2006) NF-kappaB activation by double-strand breaks.
Biochem Pharmacol 72: 1132–1141
Janssens S, Tschopp J (2006) Signals from within: the DNA-damage-
induced NF-kappaB response. Cell Death Differ 13: 773–784
Jiang BH, Liu LZ (2008) PI3K/PTEN signaling in tumorigenesis and
angiogenesis. Biochim Biophys Acta 1784: 150–158
Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin.
Mutat Res 478: 23–43
Kelland L (2007) The resurgence of platinum-based cancer chemotherapy.
Nat Rev Cancer 7: 573–584
Kleeff J, Fukahi K, Lopez ME, Friess H, Bu ¨chler MW, Sosnowski BA,
Korc M (2002) Targeting of suicide gene delivery in pancreatic cancer
cells via FGF receptors. Cancer Gene Ther 9: 522–532
Kobayashi J, Antoccia A, Tauchi H, Matsuura S, Komatsu K (2004) NBS1
and its functional role in the DNA damage response. DNA Repair 3:
855–861
Li B, Li YY, Tsao SW, Cheung ALM (2009) Targeting NF-kB signaling
pathway suppresses tumor growth, angiogenesis, and metastasis of
human esophageal cancer. Mol Cancer Ther 8: 2635–2644
Li D, Day KV, Yu S, Shi G, Liu S, Guo M, Xu Y, Sreedharan S, O’Malley Jr
BW (2002) The role of adenovirus-mediated retinoblastoma 94 in the
treatment of head and neck cancer. Cancer Res 62: 4637–4644
Li D, Duan L, Freimuth P, O’Malley Jr BW (1999) Variability of adeno-
virus receptor density influences gene transfer efficiency and
therapeutic response in head and neck cancer. Clin Cancer Res 5:
4175–4181
Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of
DNA repair pathways. Clin Cancer Res 14: 1291–1295
O’Malley Jr BW, Li D, Carney J, Rhee J, Suntharalingam M (2003) Molecular
disruption of the MRN(95) complex induces radiation sensitivity in head
and neck cancer. Laryngoscope 113: 1588–1594
Perez RP (1998) Cellular and molecular determinants of cisplatin
resistance. Eur J Cancer 34: 1535–1542
Printz MA, Gonzalez AM, Cunningham M, Gu DL, Ong M, Pierce GF,
Aukerman SL (2000) Fibroblast growth factor 2-retargeted adeno-
viral vectors exhibit a modified biolocalization pattern and display
reduced toxicity relative to native adenoviral vectors. Hum Gene Ther 11:
191–204
Qin M, Escuadro B, Sharma S, Batra RK (2005) Gene transfer mediated by
native versus fibroblast growth factor-retargeted adenoviral vectors into
lung cancer cells. Am J Respir Cell Mol Biol 32: 211–217
Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piche ´ A, Pierce GF,
Alvarez RD, Siegal GP, Douglas JT, Curiel DT (1998) Basic fibroblast
growth factor enhancement of adenovirus-mediated delivery of the
herpes simplex virus thymidine kinase gene results in augmented
therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res
4: 2455–2461
NBS1 gene delivery enhances chemosensitisation
K Araki et al
1829
British Journal of Cancer (2010) 103(12), 1822–1830 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sRiedel F, Go ¨tte K, Bergler W, Rojas W, Ho ¨rmann K (2000) Expression of
basic fibroblast growth factor protein and its down-regulation by
interferons in head and neck cancer. Head Neck 22: 183–189
Rogers BE, Douglas JT, Ahlem C, Buchsbaum DJ, Frincke J, Curiel DT
(1997) Use of a novel cross-linking method to modify adenovirus
tropism. Gene Ther 4: 1387–1392
Sagan D, Eckardt-Schupp F, Eichholtz-Wirth H (2008) Reduced expression
of SRC family kinases decreases PI3K activity in NBS1 /  lymphoblasts.
Biochem Biophys Res Commun 377: 181–186
Saito K, Khan K, Sosnowski B, Li D, O’Malley BW (2009) Cytotoxicity and
antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer
gene therapy. Laryngoscope 119: 665–674
Sewell DA, Li D, Duan L, Westra WH, O’Malley Jr BW (1997) Safety of in
vivo adenovirus-mediated thymidine kinase treatment of oral cancer.
Arch Otolaryngol Head Neck Surg 123: 1298–1302
Sun XF, Zhang H (2007) NFKB and NFKBI polymorphisms in relation to
susceptibility of tumour and other diseases. Histol Histopathol 22: 1387–1398
Tran HM, Shi G, Li G, Carney JP, O’Malley Jr BW, Li D (2004) Mutant Nbs1
enhances cisplatin-induced DNA damage and cytotoxicity in head and
neck cancer. Otolaryngol Head Neck Surg 131: 477–484
Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K,
Beckmann G, Seemanova ´ E, Cooper PR, Nowak NJ, Stumm M, Weemaes
CM, Gatti RA, Wilson RK, Digweed M, Rosenthal A, Sperling K,
Concannon P, Reis A (1998) Nibrin, a novel DNA double-strand
break repair protein, is mutated in Nijmegen breakage syndrome. Cell
93: 467–476
Wakulich C, Jackson-Boeters L, Daley TD, Wysocki GP (2002)
Immunohistochemical localization of growth factors fibroblast
growth factor-1 and fibroblast growth factor-2 and receptors fibroblast
growth factor receptor-2 and fibroblast growth factor receptor-3 in
normal oral epithelium, epithelial dysplasias, and squamous cell
carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93:
573–579
Weidner N (1995) Current pathologic methods for measuring intratumoral
microvessel density within breast carcinoma and other solid tumors.
Breast Cancer Res Treat 36: 169–180
Williams RS, Williams JS, Tainer JA (2007) Mre11-Rad50-Nbs1 is a
keystone complex connecting DNA repair machinery, double-strand
break signaling, and the chromatin template. Biochem Cell Biol 85:
509–520
Yao X, Yoshioka Y, Morishige T (2010) Adenovirus vector covalently
conjugated to polyethylene glycol with a cancer-specific promoter
suppresses the tumor growth through systemic administration. Biol
Pharm Bull 33: 1073–1076
NBS1 gene delivery enhances chemosensitisation
K Araki et al
1830
British Journal of Cancer (2010) 103(12), 1822–1830 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s